Genomic markers of resistance to targeted treatments in gastric cancer: potential new treatment strategies

Alessandra Raimondi, Federico Nichetti, Giorgia Peverelli, Maria Di Bartolomeo, Filippo De Braud, Filippo Pietrantonio

Research output: Contribution to journalArticle

Abstract

Gastric cancer is a highly heterogeneous disease, displaying a complex genomic landscape and an unfavorable outcome with standard therapies. Based on distinctive genomic alterations, novel targeted agents have been developed with the aim of personalizing treatments and improving patient outcome. However, a subgroup of patients is primarily treatment-resistant, and even in the initially sensitive population, secondary resistance emerges, thus limiting therapeutic benefit. In this review, we summarize the clinical data about standard targeted agents in gastric cancer, specifically anti-HER2 treatments and antivascular therapies. We also illustrate the available evidence regarding molecular mechanisms of resistance to these agents and we discuss potential strategies for new targeted treatments that could overcome such resistance.

Original languageEnglish
Pages (from-to)1047-1068
Number of pages22
JournalPharmacogenomics
Volume19
Issue number13
DOIs
Publication statusPublished - Aug 1 2018

Fingerprint Dive into the research topics of 'Genomic markers of resistance to targeted treatments in gastric cancer: potential new treatment strategies'. Together they form a unique fingerprint.

  • Cite this